Citigroup Increases Establishment Labs (NASDAQ:ESTA) Price Target to $50.00

Establishment Labs (NASDAQ:ESTA) had its price target upped by Citigroup from $45.00 to $50.00 in a research note released on Tuesday morning, Benzinga reports. Citigroup currently has a neutral rating on the stock.

A number of other brokerages have also recently weighed in on ESTA. Stephens reaffirmed an overweight rating and issued a $68.00 price target on shares of Establishment Labs in a research report on Wednesday, August 7th. Mizuho boosted their target price on Establishment Labs from $65.00 to $70.00 and gave the stock a buy rating in a report on Thursday, June 6th. Finally, JPMorgan Chase & Co. lowered their price target on Establishment Labs from $61.00 to $50.00 and set an overweight rating on the stock in a report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $57.60.

Establishment Labs Trading Down 6.4 %

NASDAQ:ESTA opened at $41.82 on Tuesday. The company has a market capitalization of $1.15 billion, a P/E ratio of -13.32 and a beta of 1.20. The stock’s 50 day moving average price is $42.81 and its 200 day moving average price is $47.19. The company has a debt-to-equity ratio of 4.30, a quick ratio of 2.91 and a current ratio of 4.44. Establishment Labs has a 52 week low of $16.96 and a 52 week high of $60.12.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). The business had revenue of $44.12 million for the quarter, compared to the consensus estimate of $43.10 million. Establishment Labs had a negative net margin of 54.97% and a negative return on equity of 220.67%. The firm’s revenue for the quarter was down 9.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.65) EPS. On average, research analysts forecast that Establishment Labs will post -2.2 EPS for the current fiscal year.

Insider Buying and Selling at Establishment Labs

In other news, CEO Quiros Juan Jose Chacon sold 3,641 shares of the stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $45.04, for a total value of $163,990.64. Following the completion of the sale, the chief executive officer now directly owns 210,735 shares of the company’s stock, valued at $9,491,504.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 11.44% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Hood River Capital Management LLC acquired a new stake in Establishment Labs during the second quarter worth about $43,000. Nkcfo LLC acquired a new stake in shares of Establishment Labs during the 2nd quarter worth approximately $227,000. Concurrent Investment Advisors LLC bought a new stake in shares of Establishment Labs during the first quarter valued at approximately $263,000. SG Americas Securities LLC acquired a new position in shares of Establishment Labs in the second quarter valued at $303,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Establishment Labs in the second quarter worth $373,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.